Enhanced therapeutic neovascularization by CD31-expressing cells and embryonic stem cell-derived endothelial cells engineered with chitosan hydrogel containing VEGF-releasing microtubes

Biomaterials

Volumn 63, Issue , 2015, Pages 158-167

  Lee, Sangho ^a   Valmikinathan, Chandra M ^b,d   Byun, Jaemin ^a,e   Kim, Sangsung ^a   Lee, Geehee ^a   Mokarram, Nassir ^b   Pai, S Balakrishna ^b   Um, Elisa ^a   Bellamkonda, Ravi V ^b   Yoon, Young Sup ^a,b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Emory University   (United States)

^c Yonsei University College of Medicine   (South Korea)

^d ACell Inc   (United States)

^e RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

CD31+ cells; Chitosan hydrogel; Embryonic stem cells; Lipid microtubes; Vascular regeneration

Indexed keywords

BLOOD VESSELS; CELL GROWTH; CELLS; CHITIN; CHITOSAN; CYTOLOGY; ENDOTHELIAL CELLS; HYDROGELS; STEM CELLS;

CARDIO-VASCULAR DISEASE; CELL BASED THERAPIES; CHITOSAN HYDROGEL; CYTOTOXICITY IN VITRO; EMBRYONIC STEM CELLS; MICRO-TUBES; NEO-VASCULARIZATION; VASCULAR REGENERATION;

MOLECULAR BIOLOGY;

CD31 ANTIGEN; CHITOSAN; VASCULOTROPIN; HYDROGEL; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOENGINEERING; BLOOD FLOW; CELL ENCAPSULATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EMBRYO; EMBRYONIC STEM CELL; HYDROGEL; MALE; MONONUCLEAR CELL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL CULTURE; CHEMISTRY; CYTOLOGY; ENDOTHELIUM CELL; HINDLIMB; ISCHEMIA; PATHOLOGY; TISSUE SCAFFOLD; TRANSPLANTATION; VASCULARIZATION;

ANIMALS; ANTIGENS, CD31; CELLS, CULTURED; CHITOSAN; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; HINDLIMB; HYDROGEL; ISCHEMIA; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE SCAFFOLDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84952645582     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.06.009     Document Type: Article

References (78)

1. Kinoshita M., Fujita Y., Katayama M., Baba R., Shibakawa M., Yoshikawa K., et al. Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia. Atherosclerosis 2012, 224(2):440-445.
2. Powell R.J. Update on clinical trials evaluating the effect of biologic therapy in patients with critical limb ischemia. J. Vasc. Surg. 2012, 56(1):264-266.
3. Raval Z., Losordo D.W. Cell therapy of peripheral arterial disease: from experimental findings to clinical trials. Circ. Res. 2013, 112(9):1288-1302.
4. Carmeliet P., Jain R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473(7347):298-307.
5. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146(6):873-887.
6. Barcelos L.S., Duplaa C., Krankel N., Graiani G., Invernici G., Katare R., et al. Human CD133+ progenitor cells promote the healing of diabetic ischemic ulcers by paracrine stimulation of angiogenesis and activation of Wnt signaling. Circ. Res. 2009, 104(9):1095-1102.
7. Cho H.J., Lee N., Lee J.Y., Choi Y.J., Ii M., Wecker A., et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. J. Exp. Med. 2007, 204(13):3257-3269.
8. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 2004, 94(5):678-685.
9. Leeper N.J., Hunter A.L., Cooke J.P. Stem cell therapy for vascular regeneration: adult, embryonic, and induced pluripotent stem cells. Circulation 2010, 122(5):517-526.
10. Urbich C., Aicher A., Heeschen C., Dernbach E., Hofmann W.K., Zeiher A.M., et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J. Mol. Cell. Cardiol. 2005, 39(5):733-742.
11. Yoon Y.S., Uchida S., Masuo O., Cejna M., Park J.S., Gwon H.C., et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 2005, 111(16):2073-2085.
12. Kim H., Cho H.J., Kim S.W., Liu B., Choi Y.J., Lee J., et al. CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow: novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease. Circ. Res. 2010, 107(5):602-614.
13. Kim S.W., Kim H., Cho H.J., Lee J.U., Levit R., Yoon Y.S. Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease. J. Am. Coll. Cardiol. 2010, 56(7):593-607.
14. Wang Z.Z., Au P., Chen T., Shao Y., Daheron L.M., Bai H., et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat. Biotechnol. 2007, 25(3):317-318.
15. James D., Nam H.S., Seandel M., Nolan D., Janovitz T., Tomishima M., et al. Expansion and maintenance of human embryonic stem cell-derived endothelial cells by TGFbeta inhibition is Id1 dependent. Nat. Biotechnol. 2010, 28(2):161-166.
16. Cho S.W., Moon S.H., Lee S.H., Kang S.W., Kim J., Lim J.M., et al. Improvement of postnatal neovascularization by human embryonic stem cell derived endothelial-like cell transplantation in a mouse model of hindlimb ischemia. Circulation 2007, 116(21):2409-2419.
17. Park S.W., Jun Koh Y., Jeon J., Cho Y.H., Jang M.J., Kang Y., et al. Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK/ERK and BMP4 signaling pathways. Blood 2010, 116(25):5762-5772.
18. Descamps B., Emanueli C. Vascular differentiation from embryonic stem cells: novel technologies and therapeutic promises. Vasc. Pharmacol. 2012, 56(5-6):267-279.
19. Reed D.M., Foldes G., Harding S.E., Mitchell J.A. Stem cell-derived endothelial cells for cardiovascular disease: a therapeutic perspective. Br. J. Clin. Pharmacol. 2013, 75(4):897-906.
20. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131(5):861-872.
21. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126(4):663-676.
22. Hirashima M., Kataoka H., Nishikawa S., Matsuyoshi N., Nishikawa S. Maturation of embryonic stem cells into endothelial cells in an in vitro model of vasculogenesis. Blood 1999, 93(4):1253-1263.
23. Levenberg S., Golub J.S., Amit M., Itskovitz-Eldor J., Langer R. Endothelial cells derived from human embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(7):4391-4396.
24. Yamashita J., Itoh H., Hirashima M., Ogawa M., Nishikawa S., Yurugi T., et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 2000, 408(6808):92-96.
25. Kane N.M., Meloni M., Spencer H.L., Craig M.A., Strehl R., Milligan G., et al. Derivation of endothelial cells from human embryonic stem cells by directed differentiation: analysis of microRNA and angiogenesis in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2010, 30(7):1389-1397.
26. Rufaihah A.J., Huang N.F., Jame S., Lee J.C., Nguyen H.N., Byers B., et al. Endothelial cells derived from human iPSCS increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler. Thromb. Vasc. Biol. 2011, 31(11):e72-e79.
27. Hoffmann J., Glassford A.J., Doyle T.C., Robbins R.C., Schrepfer S., Pelletier M.P. Angiogenic effects despite limited cell survival of bone marrow-derived mesenchymal stem cells under ischemia. Thorac. Cardiovasc. Surg. 2010, 58(3):136-142.
28. Huang N.F., Niiyama H., Peter C., De A., Natkunam Y., Fleissner F., et al. Embryonic stem cell-derived endothelial cells engraft into the ischemic hindlimb and restore perfusion. Arterioscler. Thromb. Vasc. Biol. 2010, 30(5):984-991.
29. Laurila J.P., Laatikainen L., Castellone M.D., Trivedi P., Heikkila J., Hinkkanen A., et al. Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model. Cytotherapy 2009, 11(6):726-737.
30. Huang N.F., Okogbaa J., Babakhanyan A., Cooke J.P. Bioluminescence imaging of stem cell-based therapeutics for vascular regeneration. Theranostics 2012, 2(4):346-354.
31. Wollert K.C., Drexler H. Clinical applications of stem cells for the heart. Circ. Res. 2005, 96(2):151-163.
32. Menasche P. Skeletal myoblasts as a therapeutic agent. Prog. Cardiovasc. Dis. 2007, 50(1):7-17.
33. Hofmann M., Wollert K.C., Meyer G.P., Menke A., Arseniev L., Hertenstein B., et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005, 111(17):2198-2202.
34. Qian H., Yang Y., Huang J., Gao R., Dou K., Yang G., et al. Intracoronary delivery of autologous bone marrow mononuclear cells radiolabeled by 18F-fluoro-deoxy-glucose: tissue distribution and impact on post-infarct swine hearts. J. Cell. Biochem. 2007, 102(1):64-74.
35. Valmikinathan C.M., Mukhatyar V.J., Jain A., Karumbaiah L., Dasari M., Bellamkonda R.V. Photocrosslinkable chitosan based hydrogels for neural tissue engineering. Soft Matter 2012, 8(6):1964-1976.
36. Takeshita S., Pu L.Q., Stein L.A., Sniderman A.D., Bunting S., Ferrara N., et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994, 90(5 Pt 2):II228-II234.
37. Takeshita S., Zheng L.P., Brogi E., Kearney M., Pu L.Q., Bunting S., et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J. Clin. Invest. 1994, 93(2):662-670.
38. Kofidis T., Nolte D., Simon A.R., Metzakis A., Balsam L., Robbins R., et al. Restoration of blood flow and evaluation of corresponding angiogenic events by scanning electron microscopy after a single dose of VEGF in a model of peripheral vascular disease. Angiogenesis 2002, 5(1-2):87-92.
39. Jain A., McKeon R.J., Brady-Kalnay S.M., Bellamkonda R.V. Sustained delivery of activated Rho GTPases and BDNF promotes axon growth in CSPG-rich regions following spinal cord injury. PloS One 2011, 6(1):e16135.
40. Johnson M.R., Lee H.J., Bellamkonda R.V., Guldberg R.E. Sustained release of BMP-2 in a lipid-based microtube vehicle. Acta Biomater. 2009, 5(1):23-28.
41. Meilander N.J., Yu X., Ziats N.P., Bellamkonda R.V. Lipid-based microtubular drug delivery vehicles. J. Control Release: Off. J. Control Release Soc. 2001, 71(1):141-152.
42. Meilander N.J., Pasumarthy M.K., Kowalczyk T.H., Cooper M.J., Bellamkonda R.V. Sustained release of plasmid DNA using lipid microtubules and agarose hydrogel. J. Control Release: Off. J. Control Release Soc. 2003, 88(2):321-331.
43. Li Z., Wu J.C., Sheikh A.Y., Kraft D., Cao F., Xie X., et al. Differentiation, survival, and function of embryonic stem cell derived endothelial cells for ischemic heart disease. Circulation 2007, 116(11 Suppl):I46-I54.
44. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 2004, 95(1):9-20.
45. Segers V.F., Lee R.T. Biomaterials to enhance stem cell function in the heart. Circ. Res. 2011, 109(8):910-922.
46. Katare R., Riu F., Rowlinson J., Lewis A., Holden R., Meloni M., et al. Perivascular delivery of encapsulated mesenchymal stem cells improves postischemic angiogenesis via paracrine activation of VEGF-A. Arterioscler. Thromb. Vasc. Biol. 2013, 33(8):1872-1880.
47. Mima Y., Fukumoto S., Koyama H., Okada M., Tanaka S., Shoji T., et al. Enhancement of cell-based therapeutic angiogenesis using a novel type of injectable scaffolds of hydroxyapatite-polymer nanocomposite microspheres. PloS One 2012, 7(4):e35199.
48. Ratliff B.B., Ghaly T., Brudnicki P., Yasuda K., Rajdev M., Bank M., et al. Endothelial progenitors encapsulated in bioartificial niches are insulated from systemic cytotoxicity and are angiogenesis competent. Am. J. Physiol. Renal. Physiol. 2010, 299(1):F178-F186.
49. Silva E.A., Kim E.S., Kong H.J., Mooney D.J. Material-based deployment enhances efficacy of endothelial progenitor cells. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(38):14347-14352.
50. Tang Z.C., Liao W.Y., Tang A.C., Tsai S.J., Hsieh P.C. The enhancement of endothelial cell therapy for angiogenesis in hindlimb ischemia using hyaluronan. Biomaterials 2011, 32(1):75-86.
51. Moon S.H., Kim J.S., Park S.J., Lee H.J., Do J.T., Chung H.M. A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation. Biomaterials 2011, 32(27):6445-6455.
52. Madihally S.V., Matthew H.W. Porous chitosan scaffolds for tissue engineering. Biomaterials 1999, 20(12):1133-1142.
53. Cao Z., Gilbert R.J., He W. Simple agarose-chitosan gel composite system for enhanced neuronal growth in three dimensions. Biomacromolecules 2009, 10(10):2954-2959.
54. Dillon G.P., Yu X., Bellamkonda R.V. The polarity and magnitude of ambient charge influences three-dimensional neurite extension from DRGs. J. Biomed. Mater. Res. 2000, 51(3):510-519.
55. Dillon G.P., Yu X., Sridharan A., Ranieri J.P., Bellamkonda R.V. The influence of physical structure and charge on neurite extension in a 3D hydrogel scaffold. J. Biomater. Sci. Polym. Ed. 1998, 9(10):1049-1069.
56. Jiang T., Kumbar S.G., Nair L.S., Laurencin C.T. Biologically active chitosan systems for tissue engineering and regenerative medicine. Curr. Top. Med. Chem. 2008, 8(4):354-364.
57. Lee S., Yoon Y.S. Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells. Br. J. Pharmacol. 2013, 169(2):290-303.
58. Goldman O., Feraud O., Boyer-Di Ponio J., Driancourt C., Clay D., Le Bousse-Kerdiles M.C., et al. A boost of BMP4 accelerates the commitment of human embryonic stem cells to the endothelial lineage. Stem Cells 2009, 27(8):1750-1759.
59. Lu S.J., Feng Q., Caballero S., Chen Y., Moore M.A., Grant M.B., et al. Generation of functional hemangioblasts from human embryonic stem cells. Nat. Methods 2007, 4(6):501-509.
60. Nourse M.B., Halpin D.E., Scatena M., Mortisen D.J., Tulloch N.L., Hauch K.D., et al. VEGF induces differentiation of functional endothelium from human embryonic stem cells: implications for tissue engineering. Arterioscler. Thromb. Vasc. Biol. 2010, 30(1):80-89.
61. Sone M., Itoh H., Yamahara K., Yamashita J.K., Yurugi-Kobayashi T., Nonoguchi A., et al. Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. Arterioscler. Thromb. Vasc. Biol. 2007, 27(10):2127-2134.
62. Yamahara K., Sone M., Itoh H., Yamashita J.K., Yurugi-Kobayashi T., Homma K., et al. Augmentation of neovascularization [corrected] in hindlimb ischemia by combined transplantation of human embryonic stem cells-derived endothelial and mural cells. PloS One 2008, 3(2):e1666.
63. Cao R., Brakenhielm E., Pawliuk R., Wariaro D., Post M.J., Wahlberg E., et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat. Med. 2003, 9(5):604-613.
64. Hattori K., Dias S., Heissig B., Hackett N.R., Lyden D., Tateno M., et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp. Med. 2001, 193(9):1005-1014.
65. Kawamoto A., Murayama T., Kusano K., Ii M., Tkebuchava T., Shintani S., et al. Synergistic effect of bone marrow mobilization and vascular endothelial growth factor-2 gene therapy in myocardial ischemia. Circulation 2004, 110(11):1398-1405.
66. Rafii S., Heissig B., Hattori K. Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors. Gene Ther. 2002, 9(10):631-641.
67. Takahashi T., Kalka C., Masuda H., Chen D., Silver M., Kearney M., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat. Med. 1999, 5(4):434-438.
68. Yau T.M., Kim C., Li G., Zhang Y., Weisel R.D., Li R.K. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation 2005, 112(9 Suppl):I123-I128.
69. Hosaka A., Koyama H., Kushibiki T., Tabata Y., Nishiyama N., Miyata T., et al. Gelatin hydrogel microspheres enable pinpoint delivery of basic fibroblast growth factor for the development of functional collateral vessels. Circulation 2004, 110(21):3322-3328.
70. Layman H., Sacasa M., Murphy A.E., Murphy A.M., Pham S.M., Andreopoulos F.M. Co-delivery of FGF-2 and G-CSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. Acta Biomater. 2009, 5(1):230-239.
71. Matsui M., Tabata Y. Enhanced angiogenesis by multiple release of platelet-rich plasma contents and basic fibroblast growth factor from gelatin hydrogels. Acta Biomater. 2012, 8(5):1792-1801.
72. Kawamura I., Takemura G., Tsujimoto A., Watanabe T., Kanamori H., Esaki M., et al. Treatment of leg ischemia with biodegradable gelatin hydrogel microspheres incorporating granulocyte colony-stimulating factor. J. Cardiovasc. Pharmacol. 2011, 57(4):416-423.
73. Li L., Okada H., Takemura G., Esaki M., Kobayashi H., Kanamori H., et al. Sustained release of erythropoietin using biodegradable gelatin hydrogel microspheres persistently improves lower leg ischemia. J. Am. Coll. Cardiol. 2009, 53(25):2378-2388.
74. Ruvinov E., Leor J., Cohen S. The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 2010, 31(16):4573-4582.
75. Silva E.A., Mooney D.J. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J. Thromb. Haemost.: JTH 2007, 5(3):590-598.
76. Cao L., Arany P.R., Wang Y.S., Mooney D.J. Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. Biomaterials 2009, 30(25):4085-4093.
77. Golub J.S., Kim Y.T., Duvall C.L., Bellamkonda R.V., Gupta D., Lin A.S., et al. Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am. J. Physiol. Heart Circ. Physiol. 2010, 298(6):H1959-H1965.
78. Shin S.H., Lee J., Lim K.S., Rhim T., Lee S.K., Kim Y.H., et al. Sequential delivery of TAT-HSP27 and VEGF using microsphere/hydrogel hybrid systems for therapeutic angiogenesis. J. Control Release: Off. J. Control Release Soc. 2013, 166(1):38-45.